AVITA Medical Reports 53% Year-Over-Year Revenue Growth in Q3 2026
AVITA Medical (RCEL) delivered strong third-quarter results for 2026, reporting total revenue of $26.1 million, a 53% increase year-over-year and a 20% sequential rise. Growth was primarily driven by the US RECELL segment, which saw revenue reach $22.4 million on increased procedure volumes and account ordering. The company also noted successful expansion in its Cohealyx product line as hospital reviews conclude. Financially, the company significantly narrowed its net loss to $6.2 million ($0.20 per share) compared to a much larger loss in the prior year. Improved manufacturing efficiencies helped push gross margins to 84%. Management also highlighted an improved liquidity position and the removal of a going concern qualification, while raising full-year revenue guidance to a range of $92 million to $94 million.
Tickers: $RCEL
Topics: financial performance gross margin net loss reduction revenue growth